Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 5,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Control Subjects Clear all
Completed Phase 4 Interventional Results available

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

NCT00261833
View directory record Official record
Conditions
Alpha1-proteinase Inhibitor Deficiency, Emphysema
Interventions
Alpha1-proteinase inhibitor, Placebo
Biological · Other
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
4
States / cities
Denver, Colorado • Miami, Florida • Hershey, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2015 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection

NCT00401947
View directory record Official record
Conditions
HCV Infection
Interventions
ACH-0137171
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
Phoenix, Arizona • La Jolla, California • San Francisco, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury

NCT01683838
View directory record Official record
Conditions
Spinal Cord Injury, Muscle Spasticity
Interventions
Fampridine-SR, Placebo
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Birmingham, Alabama • Long Beach, California • Sacramento, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 19, 2026, 4:17 PM EDT
Recruiting Phase 3 Interventional

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Telisotuzumab adizutecan, Bevacizumab, Trifluridine/Tipiracil
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
18
States / cities
Goodyear, Arizona • Springdale, Arkansas • Duarte, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.

NCT00048581
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Mobile, Alabama • Paradise Valley, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects

NCT04003402
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASP8062, Alcohol, ASP8062 Placebo, Alcohol Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 3 Interventional Results available

ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

NCT05507203
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
ABX464, Placebo
Drug
Lead sponsor
Abivax S.A.
Industry
Eligibility
16 Years and older
Enrollment
639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
54
States / cities
Dothan, Alabama • Guntersville, Alabama • Homewood, Alabama + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects

NCT02725957
View directory record Official record
Conditions
Healthy Volunteer Subjects
Interventions
Trehalose for IV Infusion, Saline 0.9% IV
Drug
Lead sponsor
Bioblast Pharma Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

NCT00642902
View directory record Official record
Conditions
Relapsing Multiple Sclerosis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Phoenix, Arizona • Atlanta, Georgia • Northbrook, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)

NCT01911637
View directory record Official record
Conditions
Healthy
Interventions
VBY-036, Placebo
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

NCT01290575
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo, BMS-820132
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects

NCT02169583
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756 Tablet, GSK1325756 Tablet Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)

NCT01669980
View directory record Official record
Conditions
Infections, Pneumonia
Interventions
Ceftaroline fosamil, IV Ceftriaxone and Vancomycin
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange County, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

A Study of A-101 Solution in Subjects With Common Warts.

NCT02669862
View directory record Official record
Conditions
Common Warts
Interventions
A-101 Solution 40, A-101 Solution 45, Vehicle Solution
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Wayne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

NCT01838694
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Ala-Cpn10, Placebo
Biological · Drug
Lead sponsor
Invion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Miami, Florida • Chicago, Illinois • Altoona, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 19, 2026, 4:17 PM EDT
Active, not recruiting No phase listed Observational

Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural History Control

NCT06529146
View directory record Official record
Conditions
Spinocerebellar Ataxias
Interventions
BHV-4157
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
909 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

NCT01831427
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Andecaliximab, Placebo to match Andecaliximab
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
6
States / cities
Monroe, Louisiana • Bethesda, Maryland • Chesterfield Township, MI 48047, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

fMRI Guided TMS Enhancement of Associative Memory Networks

NCT02749422
View directory record Official record
Conditions
Epilepsy
Interventions
MagStim RapidStim2
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Abatacept With Methotrexate- Phase IIB

NCT00162266
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept (BMS-188667), Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Huntsville, Alabama • Long Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)

NCT00093951
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SGS742
Drug
Lead sponsor
Saegis Pharmaceuticals
Industry
Eligibility
55 Years to 90 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2009 · Synced Oct 19, 2026, 4:17 PM EDT
Terminated Phase 2 Interventional Results available

Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

NCT01549977
View directory record Official record
Conditions
Angina
Interventions
Febuxostat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
21
States / cities
Carmichael, California • Fresno, California • Irvine, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Oct 19, 2026, 4:17 PM EDT
Suspended Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Oral Administration of the Phage Cocktail, VRELysin™, In Healthy and VRE-Colonized Subjects

NCT05715619
View directory record Official record
Conditions
Vancomycin-Resistant Enterococcal Colonization
Interventions
VRELysin™, Placebo
Biological · Other
Lead sponsor
Intralytix, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 19, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

NCT01738451
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436 75 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 19, 2026, 4:17 PM EDT